Preview

Russian Journal for Personalized Medicine

Advanced search

Risks of thrombosis: genotype and phenotype of blood coagulation factor V

https://doi.org/10.18705/2782-3806-2022-2-1-35-42

Abstract

The review is devoted to the key component of plasma hemostasis — blood coagulation factor V. The structure of this protein and the F5 gene encoding it, its role in the hemostasis system, interaction with other coagulation factors and the natural anticulant protein C are considered. Particular attention is paid to the genetic defects of F5, which determine both hemorrhagic complications and a hereditary tendency to increased thrombus formation. Among the latter, the Leiden mutation of coagulation factor V (FV Leiden), which is hereditary thrombophilia and is considered as a risk factor for the development of venous thromboembolic complications, is described in detail.

About the Authors

O. V. Sirotkina
Almazov National Medical Research Centre, World-Class Research Centre for Personalized Medicine; Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre “Kurchatov Institute”; Pavlov First Saint-Petersburg State Medical University
Russian Federation

Sirotkina Olga V., PhD, DSc, professor of Department of Laboratory Medicine and Genetics, Almazov National Medical Research Centre; senior researcher, Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute»; senior researcher, Pavlov First Saint-Petersburg State Medical University

Akkuratova str. 2, Saint Petersburg, 197341



A. S. Ulitina
Pavlov First Saint-Petersburg State Medical University
Russian Federation

Ulitina Anna S., PhD, senior researcher

Saint Petersburg



M. V. Kolegova
Almazov National Medical Research Centre, World-Class Research Centre for Personalized Medicine
Russian Federation

Kolegova Marina V., clinical laboratory diagnostics specialist

Saint Petersburg



E. A. Tsykalenko
City Clinical Hospital № 1
Russian Federation

Tsykalenko Elena A., clinical laboratory diagnostics speciali

Novosibirsk



A. B. Maslennikov
City Clinical Hospital № 1
Russian Federation

Maslennikov Arkadiy B., PhD, Head of the DNA diagnostics laboratory

Novosibirsk



T. V. Vavilova
Almazov National Medical Research Centre, World-Class Research Centre for Personalized Medicine
Russian Federation

Vavilova Tatiana V., MD, PhD, DSc, professor, Head of Department of Laboratory medicine and genetics

Saint Petersburg



References

1. Hoffman M, Munroe DM. A cell-based model of hemostasis. Thromb Haemost. 2001; 85:958–965.

2. Stormorken H. The discovery of factor V: a tricky clotting factor. J Thromb Haemost. 2003; 1:206–213.

3. Asselta R, Tenchini M.L, Duga S. Inherited defects of coagulation factor V: the hemorrhagic side. J Thromb Haemost. 2006; 4:26–34.

4. Gewirtz AM, Keefer M, Doshi K, et al. Biology of human megakaryocyte factor V. Blood. 1986; 67: 1639– 1648.

5. Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V. Biochemistry. 1992; 31:3777–3785.

6. Adams TE, Hockin MF, Mann KG, et al. The crystal structure of activated protein C inactivated bovine factor Va: implications for cofactor function. Proc Natl Acad Sci USA. 2004; 101:8918–8923.

7. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood. 2004; 104:1243– 1252.

8. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369(6475):64–67.

9. Van Cott EM, Khor B, Zehnder JL. Factor V Leiden. Am J Hematol. 2016; 91:46–49.

10. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Nat Acad Sci. 1993; 90:1004– 1008.

11. Norstrom E, Thorelli E, Dahlback B. Functional characterization of recombinant FV Hong Kong and FV Cambridge. Blood. 2002; 100:524–530.

12. Steen M, Norstrom E, Tholander A, et al. Functional characterization of factor V-Ile359Thr: A novel mutation associated with thrombosis. Blood. 2004; 103:3381–3387.

13. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995; 346(8983):1133–1134.

14. Калашникова Е.А., Кокровцева С.Н., Коваленко Т.Ф. и др. Частоты мутаций в генах V фактора (FV Leiden), протромбина (G20210A) и 5,10-метилентетрагидрофолатредуктазы (C677T) у русских. Медицинская генетика. 2006; 5:27–29.

15. Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients homozygous for factor V Leiden (Activated Protein C Resistance). Blood. 1995; 85(6):1504–1508.

16. Сироткина О.В., Шейдина А.М., Пчелина С.Н. и др. Генетические факторы риска развития венозных тромбозов в молодом возрасте. Вопросы современной педиатрии. 2005; 4(№ 2):42–46.

17. Сироткина О.В., Шейдина А.М., Волкова М.В. и др. Распределение аллельных вариантов генов, определяющих склонность к тромбофилии, у мужчин, перенесших инфаркт миокарда в молодом возрасте. Медицинский академический журнал. 2004; 4(№ 1):29–35.

18. Сироткина О.В., Черкас Ю.В., Меркулова А.В. и др. Генетические нарушения коагуляционного каскада и обмена гомоцистеина в генезе церебрального тромбоза. Медицинский академический журнал. 2004; 4(№ 4):23–28.

19. Сироткина О.В., Ласковец А.Б., Пчелина С.Н. и др. Молекулярно-генетический анализ факторов риска сердечно-сосудистых заболеваний — старое и новое. Медицинский алфавит. Современная лаборатория, 2012; № 1: 12–16.

20. Inbal A, Freimark D, Modan B, et al. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young men. Blood 1999; 93(7): 2186–2190.

21. Middeldorp S. Inherited thrombophilia: a double-edged sword. Hematology Am Soc Hematol Educ Program. 2016; (1):1–9.

22. Baranovskaya S, Kudinov S, Fomicheva E, et al. Age as a risk factor for myocardial infarction in Leiden mutation carriers. Molecular genetics and metabolism. 1998; 63: 155–157.

23. Rosendaal F.R., Reitsma P.H. Genetics of venous thrombosis. J Thromb Haemost. 2009; 7(Suppl.1): 301– 304.

24. Mandala E, Lafaras C, Tsioni C, et al. Prevalence of thrombophilic mutations in patients with unprovoked thromboembolic disease. A comparative analysis regarding arterial and venous disease. Hippokratia. 2012; 16(3): 250–255.

25. Dacosta A, Tardy-Poncet B, Isaaz K, et al. Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries. Heart. 1998; 80(4): 338–340.

26. Loo Keat Wei, Lyn R Griffiths, Cheah Wee Kooi, et al. Meta-analysis of factor V, factor VII, factor XII, and factor XIII-A gene polymorphisms and ischemic stroke. Medicina. 2019; 55: 101.

27. Celap I, Nikolac Gabaj N, Demarin V, et al. Genetic and lifestyle predictors of ischemic stroke severity and outcome. Neurol Sci. 2019; 40(12): 2565–2572.

28. Анисимова А.В., Гунченко А.С., Иконникова А.Ю. и др. Клинико-генетический анализ факторов риска развития острой и хронической ишемии головного мозга. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2019;119(3–2): 62–67.

29. Сироткина О.В., Улитина А.С., Пчелина С.Н. и др. Лейденская мутация фактора V свертывания крови: частота при различных сердечно-сосудистых заболеваниях и место в современных клинических рекомендациях. Сб. науч. тр. / Под ред. чл.-корр. РАН В.С. Баранова, д.б.н. А.С. Глотова. — Новосибирск: Академиздат, 2020. — С. 116–121.

30. van Vlijmen EFW, Wiewel-Verschueren S, Monster TBM, Meijer K. Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2016; 14(7): 1393–1403.

31. Gialeraki T, Valsami S, Pittaras T, et al. Oral Contraceptives and HRT Risk of Thrombosis. Clin Appl Thromb Hemost. 2018; 24(2): 217–225.

32. Hiedemann B, Vernon E, Bowie BH. ReExamining Genetic Screening and Oral Contraceptives: A Patient-Centered Review. J Pers Med. 2019; 9: 4.

33. Nanne Croles F, Nasserinejad K, Duvekotet JJ, et al. Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis. BMJ. 2017; 359.

34. Rodger MA, Walker MC, Smith GN, et al. Is thrombophilia associated with placenta-mediated pregnancy complications? A prospective cohort study. J Thromb Haemost. 2014; 12: 469–478.

35. Николаева М.Г., Момот К.А., Ясафова Н.Н. и др. Роль приобретенных факторов риска венозных тромбоэмболических осложнений у женщин репродуктивного возраста при носительстве Лейденской мутации фактора V. Флебология, 2018; 12(№ 3):101–108.

36. Николаева М.Г., Момот А.П., Сердюк Г.В. и др. АПС-резистентность, связанная с мутацией гена фактор V Лейден (генотип GA): клиническая реализация при беременности. Тромбоз, гемостаз и реология, 2018; 73(№ 1): 47–54.

37. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149(2): 315–352.


Review

For citations:


Sirotkina O.V., Ulitina A.S., Kolegova M.V., Tsykalenko E.A., Maslennikov A.B., Vavilova T.V. Risks of thrombosis: genotype and phenotype of blood coagulation factor V. Russian Journal for Personalized Medicine. 2022;2(1):35-42. (In Russ.) https://doi.org/10.18705/2782-3806-2022-2-1-35-42

Views: 342


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2782-3806 (Print)
ISSN 2782-3814 (Online)